Travis is a serial biotech entrepreneur and venture capitalist. He has co-founded several biotech and healthcare startups companies, including Azitra Inc., which is a mid-clinical stage medical dermatology company. Travis is also a venture capitalist and is a Partner at Bios Partners, which is a life science-focused venture capital firm in Texas with $300 million assets under management. He sits on the board of five portfolio companies, including IN8bio (NASDAQ: INAB), Azitra Inc., SIRPant Immunotherapeutics, Immusoft Corporation (observer), and 410 Medical, Inc. (observer). His background began in molecular biology and biochemistry after receiving scientific training at the MD Anderson Cancer Center and Duke University. He brings strong background in entrepreneurship and business and was recently acknowledged as Forbes’ 30 Under 30 in 2018. He’s also the Senior Analyst at Bios Research, which brings experience in public markets, and drug development to support venture capital investments. He also is an Associate Research Scientist in the Departments of Pediatrics and Emergency Medicine at Yale University. Mr. Whitfill has led numerous grant-funded projects, holds nearly a dozen patents, and has co-authored over 50 publications. Mr. Whitfill received degrees from Yale University (MPH), University College London (MPhil), Dallas Baptist University (BS), and is working on a PhD in innovation and economics from UCL.